MedTrace Logo

Inhaled RB042 in Healthy Adult Volunteers, Healthy Adult Smokers and Patients With Chronic Obstructive Pulmonary Disease

NCT07285122 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2026-08-12

No results posted yet for this study

Summary

This is a 4-part, randomised, double-blind, placebo-controlled, first in human study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of inhaled RB042.

Conditions

  • COPD
  • Healthy
  • Healthy Smoker
  • COPD (Chronic Obstructive Pulmonary Disease)

Interventions

DRUG

RB042

A single or multiple doses of RB042 will be administered via a nebuliser.

DRUG

Placebo inhalation solution

A single or multiple doses of placebo will be administered via a nebuliser.

Sponsors & Collaborators

  • Atisama Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-16
Primary Completion
2027-10-31
Completion
2027-10-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07285122 on ClinicalTrials.gov